ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer

March 27, 2017

Conference call and webcast on Tuesday, March 28th at 14:30 pm CET/08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Stat

Read More

ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders

March 23, 2017

LYON, France--(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orph

Read More